DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Treatment with Lenalidomide does not appear to increase the risk of leukemia progression in lower risk myelodysplastic syndrome with 5q deletion. A comparative analysis by the GFM.

Author(s): Ades L, Lebras F, Sebert M, Kelaidi C, Lamy T, Dreyfus F, Eclache V, Delaunay J, Bouscary D, Visanica S, Turlure P, Guerci Bresler A, Cabrol MP, Banos A, Blanc M, Vey N, Delmer A, Wattel E, Chevret S, Fenaux P

Affiliation(s): France;

Publication date & source: 2011-10-11, Haematologica., [Epub ahead of print]

Background. Although lenalidomide is very effective in the treatment of anemia of lower risk myelodysplastic syndromes with 5q deletion (del 5q), some concerns have been raised over the fact that it could trigger progression to acute myeloid leukemia in some patients. Design and Methods. We treated 95 transfusion dependent lower risk risk myelodysplastic syndromes with del 5q by lenalidomide (10mg/d, 3 weeks every 4 weeks), of whom 6 (6.3%) progressed to acute myeloid leukemia. This cohort was compared to a historical control cohort of 99 lower risk myelodysplastic syndromes patients with del 5q who never received Lenalidomide, using a propensity score approach that allows controlling for potential confounders in non-randomized comparisons. Results. The 4-year estimated cumulative incidence of leukemia was 9% in patients treated with lenalidomide and 15.8% in controls that did not receive lenalidomide (p=0.16). Conclusions. Using a propensity score approach, we found no significant difference in acute myeloid leukemia progression and survival from diagnosis between the cohort treated with lenalidomide and the control cohort.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017